News Column

Etubics Will Present Results of Its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting in Chicago

May 28, 2014



SEATTLE--(BUSINESS WIRE)-- Etubics Corporation, a clinical stage biotechnology company with a proprietary platform technology that delivers a long lasting "active" immune response against diseases, will present clinical data from its Phase 1/2 proof of concept clinical trials using an immunotherapeutic to treat patients with metastatic colorectal cancer or mCRC at the Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago on Sunday, June 1st, 2014 during the Developmental Therapeutics Immunotherapy session from 8:00 a.m. to 11:45 a.m. The objectives of the clinical trials were to determine the safety, immunogenicity, and overall survival of ETBX-011 during immunotherapy of mCRC patients and the data collected will be presented. Briefly, the median overall survival of the late stage mCRC patients in the trial was 11 months with a third of patients still surviving at 18 months and there was T-cell mediated immunity against a specific cancer target produced in a majority of patients with no serious side effect reported.

“We are encouraged by the data from our Phase 1/2 clinical trial using ETBX-011 for the treatment of mCRC patients and plan to initiate a larger randomized Phase 2b trial later this year to extend the evaluation of our vector gene delivery platform. Furthermore, the killer T-cell induction in this patient population certainly deserves continued study and an attempt to correlate these effects with mCRC patient anti-cancer responses. The overall survival of the 32 mCRC patients in the current Phase 1/2 trial compares favorably with other published trials at this stage,” stated Elizabeth Gabitzsch, Vice President of Research at Etubics.

Etubics Phase 1/2 mCRC trial was funded primarily through support from the National Cancer Institute or NCI. The Company was previously awarded grants for pre-clinical studies of mCRC (Grant#: 1R43CA134063-01) and the Phase 1/2 clinical trials (Contract#: HHSN261200900059C and Grant#: 2R44CA134063-02), as well as a contract from the NCI to manufacture the ETBX-011 product candidate for our next Phase 2b randomized clinical trial slated to be initiated in the second half of this year (Contract#: HHSN261201100097C).

About Etubics

Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage biotechnology company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively known as the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers. www.etubics.com

Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.





Etubics Corporation

Ms. Ines Tucakovic Clark, 206-838-5110 Ext. 110

ines@etubics.com

Source: Etubics Corporation


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Business Wire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters